R E Aarnoutse
Overview
Explore the profile of R E Aarnoutse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lemson A, Koster T, Carpaij N, Magis-Escurra C, Boeree M, Stemkens R, et al.
IJTLD Open
. 2024 Jul;
1(6):279-281.
PMID: 39021452
No abstract available.
2.
Singh K, Carvalho A, Centis R, D Ambrosio L, Migliori G, Mpagama S, et al.
Int J Tuberc Lung Dis
. 2023 Jun;
27(7):506-519.
PMID: 37353868
Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE....
3.
Alffenaar J, Stocker S, Davies Forsman L, Garcia-Prats A, Heysell S, Aarnoutse R, et al.
Int J Tuberc Lung Dis
. 2022 Jun;
26(6):483-499.
PMID: 35650702
Optimal drug dosing is important to ensure adequate response to treatment, prevent development of drug resistance and reduce drug toxicity. The aim of these clinical standards is to provide guidance...
4.
Wallenburg E, Bruggemann R, Asouit K, Teulen M, de Haan A, Franssen E, et al.
J Antimicrob Chemother
. 2020 Oct;
76(2):430-433.
PMID: 33094803
Objectives: International quality control (proficiency testing) programmes are instituted to safeguard the analytical performance of laboratories and to aid these laboratories in identifying sources of error in their analytical methods....
5.
Lange C, Aarnoutse R, Alffenaar J, Bothamley G, Brinkmann F, Costa J, et al.
Int J Tuberc Lung Dis
. 2019 Jul;
23(6):645-662.
PMID: 31315696
The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history...
6.
Stemkens R, Litjens C, Dian S, Ganiem A, Yunivita V, van Crevel R, et al.
Int J Antimicrob Agents
. 2019 Jun;
54(3):371-374.
PMID: 31202922
Tuberculous meningitis (TBM) is the most severe manifestation of tuberculosis. Pyrazinamide (PZA) is a pivotal antituberculous drug, but its dose has not been optimised for TBM. The aims of this...
7.
Aarnoutse R, Kibiki G, Reither K, Semvua H, Haraka F, Mtabho C, et al.
Antimicrob Agents Chemother
. 2017 Aug;
61(11).
PMID: 28827417
In a multiple-dose-ranging trial, we previously evaluated higher doses of rifampin in patients for 2 weeks. The objectives of the current study were to administer higher doses of rifampin for...
8.
van Boekel G, Donders A, Hoogtanders K, Havenith T, Hilbrands L, Aarnoutse R
Eur J Clin Pharmacol
. 2015 May;
71(7):811-6.
PMID: 25980838
Purpose: The aim of this study was to develop a clinically applicable limited sampling strategy for ambulatory Caucasian kidney transplant patients to estimate area under the curve in a 24-h...
9.
Te Brake L, Ruslami R, Later-Nijland H, Mooren F, Teulen M, Apriani L, et al.
Antimicrob Agents Chemother
. 2015 Mar;
59(6):3233-9.
PMID: 25801554
Nutritional status may have a profound impact on the pharmacokinetics of drugs, yet only few data are available for tuberculosis (TB) drugs. As malnutrition occurs frequently among TB patients, we...
10.
Lempers V, Alffenaar J, Touw D, Burger D, Uges D, Aarnoutse R, et al.
J Antimicrob Chemother
. 2014 Jul;
69(11):2988-94.
PMID: 25006236
Objectives: Since 2007 the Dutch Association for Quality Assessment in Therapeutic Drug Monitoring (KKGT) has organized an international interlaboratory proficiency testing (PT) programme for measurement of antifungal drugs in plasma....